INTRODUCTION
Apolipoprotein C-III (apoC-III), synthesized by the liver and intestine, is an inhibitor of LPL-mediated lipolysis and hepatic clearance of triglyceride-rich lipoproteins. ApoC-III overproduction is linked with hypertriglyceridemia and atherosclerosis. ApoC-III may also play an intracellular role in hepatic VLDL assembly/secretion. Little is known about the role of apoC-III in the intestine, although it is secreted on chylomicrons coincident with triglyceride absorption.
HYPOTHESIS
Given that overexpression of apoC-III results in high plasma triglyceride levels, we hypothesized that it might also stimulate intestinal triglyceride transport, thereby exacerbating plasma hypertriglyceridemia in human apoC-III transgenic (h-apoC-III tg) mice.
METHODS
28-30 gram male h-apoC-III tg (on a C57BL/6J background) were fitted with both a mesenteric lymph cannula and a duodenal feeding tube, and received a continuous intraduodenal infusion of triglyceride (6 μmol of 3[H]-Triolein in 0.3ml of phosphate-buffered saline) for 6 hours with hourly lymph samples collected (n=11-12). At the end of the infusion period, luminal and mucosal contents and tissue samples were isolated. An advantage of this lymph fistula model is the ability to sample lymph continuously throughout the triglyceride infusion period while avoiding confounding effects of anesthesia and stomach emptying.
RESULTS
h-apoC-III tg mice had a decrease in lymph flow and a 43% reduction in lymphatic 3[H]-triglyceride transport compared to WT mice. The h-apoC-III tg mice had 10.0±2.3% of the total dose of 3[H]-triglyceride remaining in intestinal lumen; which was significantly higher than the 3.1±0.4% observed in WT mice. Thin layer chromatographic analysis of the luminal contents showed that h-apoC-III tg mice, as opposed to WT controls, had a significantly higher percentage of fatty acid. There were no significant differences in the luminal triglyceride, diglyceride, and monoglyceride composition between groups.
CONCLUSION
Our studies reveal a novel role for apoC-III in decreasing intestinal triglyceride transport distinct from its extracellular roles in plasma on lipoprotein lipase, and its intracellular role in hepatic VLDL synthesis and secretion.
The human apolipoprotein C-II gene sequence contains a novel chromosome 19-specific minisatellite in its third intron.
